May 2017 tender notification

Tender Closed

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2015/16 Invitation to Tender, dated 6 November 2015 and the 2016/17 Invitation to Tender, dated 3 November 2016.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website(external link).

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (http://www.pgnz.org.nz/pharmacode(external link)) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors(external link)). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name Presentation;
Pack size and type
Current subsidy (and price) New subsidy (and price) Sole supply brand
(Supplier)
Date of subsidy change Sole Subsidised Supply date
Brimonidine tartrate* Eye drops 0.2%;
5 ml OP bottle
$4.32 $4.29 Arrow-Brimonidine
(Actavis)
1 December 2017 1 March 2018
Neostigmine metisulfate Inj 2.5 mg per ml, 1 ml;
50 ampoules
$98.00 $98.00 AstraZeneca
(AstraZeneca)
1 September 2017 1 December 2017
Rifaximin Tab 550 mg;
56 tablets; blister pack
$625.00 $625.00 Xifaxan
(Norgine)
1 July 2017 1 October 2017
*This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2016/17 Invitation To Tender.

Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: 

Chemical name Presentation;
Pack size and type
Current subsidy (and price) New subsidy (and price) Sole supply brand (Supplier) Date of listing/subsidy change for tender winning brand Date of reference pricing of other listed brands Sole Subsidised Supply date (and delisting of other listed brands) Brand (Supplier) affected by reference pricing and delisting
Anastrozole* Tab 1 mg;
30 tablets; blister pack
$26.55 $5.04 Rolin
(Rex Medical)
1 November 2017 1 January 2018 1 April 2018 Aremed (AFT) Arimidex (AstraZeneca) DP-Anastrozole (Douglas)
Bisoprolol fumarate** Tab 2.5 mg;
90 tablets; blister pack
$2.40 per 30 tablets $3.53 Bosvate
(Douglas)
1 July 2017 1 September 2017 1 December 2017 Bosvate (Douglas)
30 tablet pack
Bisoprolol fumarate** Tab 5 mg;
90 tablets; blister pack
$3.50 per 30 tablets $5.15 Bosvate
(Douglas)
1 July 2017 1 September 2017 1 December 2017 Bosvate (Douglas)
30 tablet pack
Bisoprolol fumarate** Tab 10 mg;
90 tablets; blister pack
$6.40 per 30 tablets $9.40 Bosvate
(Douglas)
1 July 2017 1 September 2017 1 December 2017 Bosvate(Douglas)
30 tablet pack
Ethinyloestradiol with levonorgestrel Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets;
84 tablets; blister pack
$2.65 $2.18 Microgynon 20 ED
(Bayer)
1 November 2017 1 January 2018 1 April 2018 Ava 20 ED
(Actavis)
Ethinyloestradiol with levonorgestrel Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets;
84 tablets; blister pack
$2.30 $1.77 Levlen ED
(Bayer)
1 November 2017 1 January 2018 1 April 2018 Ava 30 ED
(Actavis)
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg;
30 sachets
$7.65 $6.78 Molaxole
(Mylan)
1 December 2017 1 February 2018 1 May 2018 Lax-Sachets
(AFT)

* Brand switch fee of $4.50 is payable for this product from 1 April 2018 until 1 July 2018.

**The three months dispensed all-at-once (Stat dispensing) rule will be added to bisoprolol fumarate tablets from 1 December 2017.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical Name Presentation;
Pack size and type
Current price New price Hospital Supply Brand (Supplier) DVLimit Listing date Hospital Supply Status date
Brimonidine tartrate* Eye drops 0.2%;
5 ml bottle
$4.32 $4.29 Arrow-Brimonidine
(Actavis)
1% 1 December 2017 1 February 2018
Neostigmine metisulfate Inj 2.5 mg per ml, 1 ml;
50 ampoules
$98.00 $98.00 AstraZeneca
(AstraZeneca)
1% 1 September 2017 1 November 2017
Rifaximin Tab 550 mg;
56 tablets; blister pack
$625.00 $625.00 Xifaxan
(Norgine)
1% 1 July 2017 1 September 2017
Ropivacaine hydrochloride Inj 2 mg per ml, 10 ml ampoule;
5 ampoules
$9.05 $8.80 Ropivacaine Kabi
(Fresenius Kabi)
1% 1 July 2017 1 September 2017
Ropivacaine hydrochloride Inj 2 mg per ml, 20 ml ampoule;
5 ampoules
$9.50 $9.20 Ropivacaine Kabi
(Fresenius Kabi)
1% 1 July 2017 1 September 2017
Ropivacaine hydrochloride Inj 7.5 mg per ml, 10 ml ampoule;
5 ampoules
$10.20 $9.90 Ropivacaine Kabi
(Fresenius Kabi)
1% 1 July 2017 1 September 2017
Ropivacaine hydrochloride Inj 7.5 mg per ml, 20 ml ampoule;
5 ampoules
$12.50 $12.15 Ropivacaine Kabi
(Fresenius Kabi)
1% 1 July 2017 1 September 2017
Ropivacaine hydrochloride Inj 10 mg per ml, 10 ml ampoule; 5 ampoules $10.90 $10.55 Ropivacaine Kabi(Fresenius Kabi) 1% 1 July 2017 1 September 2017
Ropivacaine hydrochloride` Inj 10 mg per ml, 20 ml ampoule; 5 ampoules $16.30 $15.80 Ropivacaine Kabi(Fresenius Kabi) 1% 1 July 2017 1 September 2017
Suxamethonium chloride Inj 50 mg per ml, 2 ml ampoule; 50 ampoules $78.00 $78.00 AstraZeneca
(AstraZeneca)
1% 1 September 2017 1 November 2017
Zinc and castor oil Oint BP; 20 g tube $1.39 $1.26 healthE
(Jaychem)
1% 1 September 2017 1 November 2017
*This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedules 6, clause 3.1 (b)(II) of the 2016/17 Invitation To Tender.

Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name Presentation;
Pack size and type
Current price New price Hospital Supply Brand (Supplier) DVLimit Listing date Hospital Supply Status date Brand (Supplier) affected by delisting
Anastrozole Tab 1 mg;
30 tablets; blister pack
$26.55 $5.04 Rolin
(Rex Medical)
1% 1 November 2017 1 January 2018 Aremed (AFT) DP-Anastrozole (Douglas)
Bisoprolol fumarate Tab 2.5 mg;
90 tablets; blister pack
$2.40 per 30 tablets $3.53 Bosvate
(Douglas)
1% 1 July 2017 1 September 2017 Bosvate (Douglas) 30 tablet pack
Bisoprolol fumarate Tab 5 mg;
90 tablets; blister pack
$3.50 per 30 tablets $5.15 Bosvate
(Douglas)
1% 1 July 2017 1 September 2017 Bosvate (Douglas) 30 tablet pack
Bisoprolol fumarate Tab 10 mg;
90 tablets; blister pack
$6.40 per 30 tablets $9.40 Bosvate
(Douglas)
1% 1 July 2017 1 September 2017 Bosvate (Douglas) 30 tablet pack
Ceftazidime Inj 1 g vial;
1 vial
$1.55 $2.20 Hospira Ceftazidime
(Pfizer)
1% 1 January 2018 1 March 2018 Fortum (GSK)
Cefuroxime Inj 750 mg vial;
10 vials
$3.70 per 5 vials $9.85 Cefuroxime Actavis
(Actavis)
1% 1 December 2017 1 February 2018 Zinacef (GSK)
Cefuroxime Inj 1.5 g vial;
10 vials
$1.30 per vial $14.36 Cefuroxime Actavis
(Actavis)
1% 1 December 2017 1 February 2018 Zinacef (GSK)
Ethinyloestradiol with levonorgestrel Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets;
84 tablets; blister pack
$2.65 $2.18 Microgynon 20 ED
(Bayer)
1% 1 November 2017 1 January 2018 Ava 20 ED (Actavis)
Ethinyloestradiol with levonorgestrel Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets;
84 tablets; blister pack
$2.30 $1.77 Levlen ED
(Bayer)
1% 1 November 2017 1 January 2018 Ava 30 ED (Actavis)
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg;
28 sachets
$7.65 $6.78 Molaxole
(Mylan)
1% 1 December 2017 1 February 2018 Lax-Sachets (AFT)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2016/17 Invitation to Tender, dated 3 November 2016:

2015/16 Invitation to Tender

Chemical Name Line Item
Condom lubricating jelly <200 ml
Condoms Female condom
Dorzolamide Eye drops 2%

2016/17 Invitation to Tender

Chemical Name Line Item
Calcium carbonate Tab eff 0.875 - 1.75 g (0.5 g - 1 g elemental)
Cefuroxime Oral suspension 25 mg per ml
Cefuroxime Oral suspension 50 mg per ml
Cidofovir Inj 75 mg per ml, 5 ml
Ciprofloxacin with Hydrocortisone Ear drops 0.2% with hydrocortisone 1%
Coal tar Shampoo 4% (pack size of 100 ml or less)
Cyclopentolate hydrochloride Eye drops 1%
Fosfomycin Powder for oral solution, 3 g sachet
Hydrocortisone Butyrate Oint 0.1% (pack size of 100 g or less)
Ivermectin Cream 1%
Lithium carbonate Cap 250 mg
Lopinavir with Ritonavir Oral liq 80 mg with ritonavir 20 mg per ml
Lopinavir with ritonavir Tab 100 mg with ritonavir 25 mg
Mefloquine hydrochloride Tab 250 mg
Methadone hydrochloride Inj 10 mg per ml, 1 ml
Methotrexate Inj 100 mg per ml, 10 ml
Orphenadrine Citrate Tab 100 mg
Paclitaxel Inj 150 mg
Paclitaxel Inj 600 mg
Pivmecillinam Tab 200 mg
Prednisolone acetate Eye drops 0.12%
Pyrimethamine Tab 25 mg
Streptomycin sulphate Inj 400 mg per ml, 2.5 ml
Testosterone Transdermal patch 5 mg
Testosterone Transdermal patch 2.5 mg
Tobramycin Eye drops 0.3%
Tobramycin Eye oint 0.3%
Trimethoprim Tab 100 mg
Trimethoprim Oral liq
Trimethoprim with sulphamethoxazole [Co-trimoxazole] Tab trimethoprim 80 mg and sulphamethoxazole 400 mg
Trimethoprim with sulphamethoxazole [Co-trimoxazole] Tab trimethoprim 160 mg and sulphamethoxazole 800 mg
Verapamil hydrochloride Tab long-acting 120 mg
Verapamil hydrochloride Tab 40 mg
Verapamil hydrochloride Tab 80 mg
Verapamil hydrochloride Tab long-acting 240 mg

For products included in the 2014/15, 2015/16 and 2016/17 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. 

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.